Literature DB >> 26161988

Foveal Sparing of Reticular Drusen in Eyes With Early and Intermediate Age-Related Macular Degeneration.

Julia S Steinberg, Monika Fleckenstein, Frank G Holz, Steffen Schmitz-Valckenberg.   

Abstract

PURPOSE: To analyze the central distribution of reticular drusen (RDR) in eyes with early and intermediate AMD without soft drusen or pigmentary changes within the central subfield using confocal scanning laser ophthalmoscopy (cSLO) and spectral-domain optical coherence tomography (SD-OCT).
METHODS: Fifty-two eyes of 46 subjects (median age: 76.3 years, interquartile range [IQR], 71-80) were examined by simultaneous combined near-infrared cSLO and raster SD-OCT imaging. The appearance and the topographic distribution of RDR were analyzed within the macula area using the Early Treatment Diabetic Retinopathy Study grid. In addition, longitudinal examinations during an observation period of at least 6 months were included (median observation time: 1.5 years, IQR, 0.9-2.8).
RESULTS: The RDR involvement within the central subfield (46%) was less compared with the surrounding subfields (62%-100%), slices (67%-100%), and zones (94%-100%) (P < 0.001). RDR were typically distributed as one continuous zone around the fovea in an incomplete or complete ring-shaped pattern, whereas the fovea itself was either spared or only a few lesions were present. Over time, the RDR density increased and new RDR lesions occurred at the border of the RDR zone toward a closure of the ring-shaped pattern. Within the fovea, development of RDR was observed in 8 of 28 eyes.
CONCLUSIONS: The fovea appears to be less vulnerable to RDR development as compared with peripheral macula areas. Factors for initial sparing of the foveal retina are yet unknown but may relate to topographic differences of choroidal blood flow and/or photoreceptor distribution.

Entities:  

Mesh:

Year:  2015        PMID: 26161988     DOI: 10.1167/iovs.15-16657

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

1.  Prevalence of reticular pseudodrusen in an elderly UK Caucasian population-The Bridlington Eye Assessment Project (BEAP): a cross-sectional study (2002-2006).

Authors:  Craig Wilde; Ali Poostchi; Rajnikant L Mehta; Jonathan G Hillman; Hamish K MacNab; Marco Messina; Marco Morales; Stephen A Vernon; Winfried M Amoaku
Journal:  Eye (Lond)       Date:  2018-03-01       Impact factor: 3.775

2.  The Clinical Spectrum and Disease Course of DRAM2 Retinopathy.

Authors:  Tjaša Krašovec; Marija Volk; Maja Šuštar Habjan; Marko Hawlina; Nataša Vidović Valentinčič; Ana Fakin
Journal:  Int J Mol Sci       Date:  2022-07-02       Impact factor: 6.208

3.  Patterns of Fundus Autofluorescence Lifetimes In Eyes of Individuals With Nonexudative Age-Related Macular Degeneration.

Authors:  Lydia Sauer; Rebekah H Gensure; Karl M Andersen; Lukas Kreilkamp; Gregory S Hageman; Martin Hammer; Paul S Bernstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-03-20       Impact factor: 4.799

4.  Spatial Dissociation of Subretinal Drusenoid Deposits and Impaired Scotopic and Mesopic Sensitivity in AMD.

Authors:  Yuhua Zhang; SriniVas R Sadda; David Sarraf; Thomas A Swain; Mark E Clark; Kenneth R Sloan; William E Warriner; Cynthia Owsley; Christine A Curcio
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-02-01       Impact factor: 4.799

5.  Macular Atrophy Development and Subretinal Drusenoid Deposits in Anti-Vascular Endothelial Growth Factor Treated Age-Related Macular Degeneration.

Authors:  Anna V Zarubina; Orly Gal-Or; Carrie E Huisingh; Cynthia Owsley; K Bailey Freund
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-12-01       Impact factor: 4.799

6.  Longitudinal Analysis of Structural and Functional Changes in Presence of Reticular Pseudodrusen Associated With Age-Related Macular Degeneration.

Authors:  Marlene Sassmannshausen; Maximilian Pfau; Sarah Thiele; Rolf Fimmers; Julia S Steinberg; Monika Fleckenstein; Frank G Holz; Steffen Schmitz-Valckenberg
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-08-03       Impact factor: 4.799

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.